Top

Published in:

01-07-2019 | Mastectomy | Epidemiology

Evolution in practice patterns of axillary management following mastectomy in patients with 1–2 positive sentinel nodes

Authors: Anna Weiss, Heather Lin, Gildy V. Babiera, Isabelle Bedrosian, Simona F. Shaitelman, Yu Shen, Henry M. Kuerer, Elizabeth A. Mittendorf, Abigail S. Caudle, Kelly K. Hunt, Rosa F. Hwang

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Abstract

Purpose

The optimal management of breast cancer patients with a positive sentinel lymph node (SLN) who undergo mastectomy remains controversial. This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database.

Methods

The NCDB was queried for cT1–2N0 breast cancer patients treated with mastectomy between 2006 and 2014 who had 1-2 positive SLNs. Patients receiving neoadjuvant chemotherapy were excluded. Axillary management included SLN dissection (SLND) alone, axillary lymph node dissection (ALND), post-mastectomy radiation (PMRT) alone, and ALND + PMRT. Trends of axillary management and patient characteristics were examined.

Results

Among 12,190 patients who met study criteria, the use of ALND dropped with a corresponding increase in other approaches. In 2006, 34% of patients had SLND alone, 47% ALND, 8% PMRT and 11% ALND + PMRT. By 2014, 37% had SLND, 23% ALND, 27% PMRT and 13% ALND + PMRT. Patients who underwent SLND alone were older (mean 60.6 years) with more comorbidities (Charlson–Deyo score > 2), smaller primary tumors (mean 2.1 cm), well-differentiated histology, hormone receptor-positive, HER2-negative tumors, without lymphovascular invasion (all P values < 0.01). Treatment with SLND alone was more likely if patients had only one positive SLN (P < 0.001) or micrometastatic disease (P < 0.001), and were treated at community centers compared with academic centers (P < 0.001).

Conclusions

The management of breast cancer patients undergoing mastectomy with positive SLNs has evolved over time with decreased use of ALND and increased use of radiation. Some patient subsets are underrepresented in recent clinical trials, and therefore, future trials should focus on these patients.

Available only for authorised users

Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252 (3):426-432; (discussion 432–423)

Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569–575. https://doi.org/10.1001/jama.2011.1090 CrossRefPubMedPubMedCentral

Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK (2016) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg 264(3):413–420. https://doi.org/10.1097/SLA.0000000000001863 CrossRefPubMedPubMedCentral

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318(10):918–926. https://doi.org/10.1001/jama.2017.11470 CrossRefPubMedPubMedCentral

Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA (2012) American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol 19(10):3144–3151. https://doi.org/10.1245/s10434-012-2531-z CrossRefPubMedPubMedCentral

Yao K, Liederbach E, Pesce C, Wang CH, Winchester DJ (2015) Impact of the american college of surgeons oncology group z0011 randomized trial on the number of axillary nodes removed for patients with early-stage breast cancer. J Am Coll Surg 221(1):71–81. https://doi.org/10.1016/j.jamcollsurg.2015.02.035 CrossRefPubMed

Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS (2017) Expanding implementation of ACOSOG Z0011 in surgeon practice. Clin Breast Cancer 13(17):30412–30413

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 14(4):297–305. https://doi.org/10.1016/S1470-2045(1013)70035-70034 CrossRefPubMedPubMedCentral

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310. https://doi.org/10.1016/S1470-2045(1314)70460-70467 CrossRefPubMedPubMedCentral

10.

Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27(18):2946–2953. https://doi.org/10.1200/JCO.2008.2919.5750 CrossRefPubMed

11.

Fu Y, Chung D, Cao MA, Apple S, Chang H (2014) Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer? Ann Surg Oncol 21(13):4109–4123. https://doi.org/10.1245/s10434-10014-13814-10433 CrossRefPubMed

12.

Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, Rogers K, Arnold B, Eaton A, Catalano J, McCormick B, Powell S, Ho A (2012) Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol 19(12):3762–3770. https://doi.org/10.1245/s10434-10012-12386-10433 CrossRefPubMed

13.

Snow R, Reyna C, Johns C, Lee MC, Sun W, Fulp WJ, Kiluk JV, Laronga C (2015) Outcomes with and without axillary node dissection for node-positive lumpectomy and mastectomy patients. Am J Surg 210(4):685–693. https://doi.org/10.1016/j.amjsurg.2015.1005.1004 CrossRefPubMed

14.

FitzSullivan E, Bassett RL, Kuerer HM, Mittendorf EA, Yi M, Hunt KK, Babiera GV, Caudle AS, Black DM, Bedrosian I, Reyna C, Teshome M, Meric-Bernstam F, Hwang R (2017) Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. Ann Surg Oncol 24(3):652–659. https://doi.org/10.1245/s10434-10016-15605-10435 CrossRefPubMed

15.

Gaines S, Suss N, Barrera E, Pesce C, Kuchta K, Winchester DJ, Yao K (2018) Axillary Surgery for Early-Stage, Node-Positive Mastectomy Patients and the Use of Postmastectomy Chest Wall Radiation Therapy. Ann Surg Oncol 25(8):2220–2228. https://doi.org/10.1245/s10434-018-6409-6 CrossRefPubMed

16.

American College of Surgeons, National Cancer Database. https://www.facs.org/quality-programs/cancer/ncdb. Accessed 19 July 2018

17.

Mittendorf EA, Hunt KK, Boughey JC, Bassett R, Degnim AC, Harrell R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Hwang RF (2012) Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg 255(1):109–115. https://doi.org/10.1097/SLA.1090b1013e318238f318461 CrossRefPubMedPubMedCentral

18.

Breast Cancer Nomogram to Predict Additional Positive Non-SLN, without Neoadjuvant Chemotherapy. The University of Texas MD Anderson Cancer Center. http://www3.mdanderson.org/app/medcalc/bc_nomogram2/index.cfm?pagename=nsln&sln=Category. Accessed 21 Aug 2018

19.

Woolson RF, Clarke WR, Wiley Online Library (Online service) (2002) Statistical methods for the analysis of biomedical data

20.

Kenny TC, Dove J, Shabahang M, Woll N, Hunsinger M, Morgan A, Blansfield J (2016) Widespread implications of ACOSOG Z0011: effect on total mastectomy patients. Am Surg 82(1):53–58PubMed

21.

Reyna C, Kiluk JV, Frelick A, Khakpour N, Laronga C, Lee MC (2015) Impact of axillary ultrasound (AUS) on axillary dissection in breast conserving surgery (BCS). J Surg Oncol 111(7):813–818. https://doi.org/10.1002/jso.23885 CrossRefPubMed

22.

Crawford JD, Ansteth M, Barnett J, Glissmeyer M, Johnson NG (2013) Routine completion axillary lymph node dissection for positive sentinel nodes in patients undergoing mastectomy is not associated with improved local control. Am J Surg 205(5):581–584. https://doi.org/10.1016/j.amjsurg.2013.02.001 (discussion 584) CrossRefPubMed

23.

Mamtani A, Patil S, Stempel M, Morrow M (2017) Axillary micrometastases and isolated tumor cells are not an indication for post-mastectomy radiotherapy in stage 1 and 2 breast cancer. Ann Surg Oncol 24(8):2182–2188. https://doi.org/10.1245/s10434-017-5866-7 CrossRefPubMedPubMedCentral

24.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, Hudis CA, Hwang ES, Kirshner JJ, Morrow M, Salerno KE, Sledge GW Jr, Solin LJ, Spears PA, Whelan TJ, Somerfield MR, Edge SB (2017) Postmastectomy Radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Ann Surg Oncol 24(1):38–51. https://doi.org/10.1245/s10434-016-5558-8 CrossRefPubMed

25.

Rusthoven CG, Rabinovitch RA, Jones BL, Koshy M, Amini A, Yeh N, Jackson MW, Fisher CM (2016) The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis. Ann Oncol 27(5):818–827. https://doi.org/10.1093/annonc/mdw1046 CrossRefPubMed

26.

In H, Bilimoria KY, Stewart AK, Wroblewski KE, Posner MC, Talamonti MS, Winchester DP (2014) Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol 21(5):1520–1529. https://doi.org/10.1245/s10434-10014-13516-x CrossRefPubMed

27.

Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N (2017) 21-Gene recurrence score and locoregional recurrence in node-positive/er-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw259 CrossRefPubMedPubMedCentral

28.

Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28(10):1677–1683CrossRefPubMedPubMedCentral

29.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. https://doi.org/10.1056/nejmoa1804710 CrossRefPubMedPubMedCentral

30.

Haffty BG, Buchholz TA (2010) Molecular predictors of locoregional recurrence in breast cancer: ready for prime time? J Clin Oncol 28(10):1627–1629. https://doi.org/10.1200/jco.2009.27.1080 CrossRefPubMed

Title: Evolution in practice patterns of axillary management following mastectomy in patients with 1–2 positive sentinel nodes
Authors: Anna Weiss
Heather Lin
Gildy V. Babiera
Isabelle Bedrosian
Simona F. Shaitelman
Yu Shen
Henry M. Kuerer
Elizabeth A. Mittendorf
Abigail S. Caudle
Kelly K. Hunt
Rosa F. Hwang
Publication date: 01-07-2019
Publisher: Springer US
Keyword: Mastectomy
Published in: Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05243-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2019

A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer

Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy

Does every woman presenting with malignant calcifications require a post lumpectomy mammogram?

Circulating adipose stromal cells as a response biomarker in phase II energy balance trials of obese breast cancer survivors and high-risk women

Post-mastectomy immediate breast reconstruction is oncologically safe in well-selected T4 locally advanced breast cancer: a large population-based study and matched case–control analysis

Correction to: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer